In multivariable analysis, presence of an HCC (OR 0.077, 95%-CI 0.007–0.904), IFN treatment experience (OR 0.396, 95%-CI 0.194–0.798), an IFN-based therapy (OR 0.111; 95%-CI 0.054–0.218) and LS at baseline (OR 0.940, 95%-CI 0.915–0.964) were associated with treatment failure, whereas DAA treatment experience (OR 0.541; 95%-CI 0.234–1.303) or a specific GT were not risk factors in this cohort (Table 3). This evidence concerns the gene IFNA1 and hepatocellular carcinoma.